Growth Hormone Axis Research blend
CJC-1295 (no DAC) + Ipamorelin CP10
GHRH + GHS blend
Research blend of CJC-1295 (no DAC), a GHRH analogue, and ipamorelin, a ghrelin-receptor agonist, studied for growth hormone release.
Evidence level. Evidence comes mainly from animal or other preclinical models. For a blend, the rating covers the combination itself; each component has its own profile. About the badges
- Class
- GHRH + GHS blend
- Category
- Growth Hormone Axis
- Type
- Research blend
- Abbreviation
- CP10
- Development and regulatory status
- Not approved; research blend of two investigational peptides
Blend composition
CJC-1295 no DAC 5 mg + Ipamorelin 5 mg
Each component is profiled separately in the catalogue: CJC-1295 (no DAC), Ipamorelin, Tesamorelin + Ipamorelin.
What researchers study
Two-component research blend pairing a modified GHRH(1-29) analogue with ipamorelin, a ghrelin-receptor (GHS-R1a) agonist. The components act on separate pituitary receptors, so the blend is studied for combined effects on growth hormone release.
Research areas
- Combined GHRH and ghrelin-receptor pathway signalling
- Synergy of two GH secretagogue mechanisms
- Pituitary somatotroph responses in cells and animals
- Analytical characterisation of two-peptide blends
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture and rodent
Ipamorelin alone released GH from rat pituitary cells and in rats and swine with potency similar to GHRP-6
- review
A 2026 review notes uncertainty about composition and combination practices for unregulated GH-axis peptides, contrasting them with peer-reviewed evidence
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- CJC-1295 (no DAC)GHRH-analogue component of the blend
- Ipamorelinghrelin-receptor agonist component of the blend
- Tesamorelin + Ipamorelinanalogous GHRH-analogue plus ghrelin-receptor agonist blend
